# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001104659-26-018708
**Filing Date:** 2026-2
**Character Count:** 35538
**Document Hash:** 8c46f25fd10acb0296f19e5034f75035
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-018708.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-26-018708

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260223

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-293636
- **FILM NUMBER:** 26666883

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

**Filed Pursuant to Rule 433**

**Dated February 23, 2026**

**Registration Statement No. 333-293636**

FINAL TERM SHEET

Floating Rate Notes due 2029

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $1000000000 |
| Interest: | The Floating Rate Notes will bear interest at a floating rate equal to a benchmark rate, which will initially be Compounded SOFR (as defined in the Prospectus Supplement under "Description of Notes"), plus a spread of 0.500% per year, accruing from March 9, 2026. |
| Maturity: | March 9, 2029 |
| Price to Public: | 100.000% plus accrued interest, if any, from March 9, 2026 |
| Interest Rate Basis: | Compounded SOFR |
| Spread to Compounded SOFR: | +50 bps |
| Interest Payment Dates: | Each March 9, June 9, September 9 and December 9, commencing June 9, 2026 |
| Interest Payment Determination Date: | The date that is two U.S. Government Securities Business Days before each interest payment date. |
| Interest Period: | The period from, and including, the most recent interest payment date for the Floating Rate Notes (or, with respect to the initial interest period only, from and including March 9, 2026) to, but excluding, the next succeeding interest payment date for the Floating Rate Notes, or in the case of the last such period, from, and including, the interest payment date for the Floating Rate Notes immediately preceding the maturity date to, but excluding, the maturity date. |
| Observation Period: | In respect of each interest period, the period from, and including, the date that is two U.S. Government Securities Business Days preceding the first date in such interest period to, but excluding, the Interest Payment Determination Date for such interest period. |
| Settlement Date: | March 9, 2026 |
| Optional Redemption Provisions: | The Floating Rate Notes are not redeemable prior to maturity, with the exception of a Special Mandatory Redemption. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BY5 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |
| Calculation Agent: | U.S. Bank Trust Company, National Association |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

3.700% Notes due 2029

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2250000000 |
| Coupon: | 3.700% |
| Maturity: | March 9, 2029 |
| Price to Public: | 99.873% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 3.745% |
| Benchmark Treasury: | 3.500% due February 15, 2029 |
| Spread to Benchmark Treasury: | +30 bps |
| Treasury Price and Yield: | 100-04 7/8 / 3.445% |
| Coupon Dates: | Semiannually on March 9 and September 9 |
| First Coupon: | September 9, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | February 9, 2029 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 5 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BR0 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

4.000% Notes due 2031

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2500000000 |
| Coupon: | 4.000% |
| Maturity: | March 15, 2031 |
| Price to Public: | 99.855% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.032% |
| Benchmark Treasury: | 3.750% due January 31, 2031 |
| Spread to Benchmark Treasury: | +45 bps |
| Treasury Price and Yield: | 100-24 / 3.582% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | February 15, 2031 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BS8 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> BNP Paribas Securities Corp. |
| Co-Managers: | Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

4.300% Notes due 2033

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2750000000 |
| Coupon: | 4.300% |
| Maturity: | March 15, 2033 |
| Price to Public: | 99.813% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.331% |
| Benchmark Treasury: | 4.000% due January 31, 2033 |
| Spread to Benchmark Treasury: | +55 bps |
| Treasury Price and Yield: | 101-10 1/4 / 3.781% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | January 15, 2033 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date.<br>|

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BT6 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> MUFG Securities Americas Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

4.650% Notes due 2036

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $3750000000 |
| Coupon: | 4.650% |
| Maturity: | March 15, 2036 |
| Price to Public: | 99.753% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.681% |
| Benchmark Treasury: | 4.125% due February 15, 2036 |
| Spread to Benchmark Treasury: | +65 bps |
| Treasury Price and Yield: | 100-24 + / 4.031% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | December 15, 2035 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BU3 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> SG Americas Securities, LLC |
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

4.750% Notes due 2038

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2000000000 |
| Coupon: | 4.750% |
| Maturity: | March 15, 2038 |
| Price to Public: | 99.718% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.781% |
| Benchmark Treasury: | 4.125% due February 15, 2036 |
| Spread to Benchmark Treasury: | +75 bps |
| Treasury Price and Yield: | 100-24 + / 4.031% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | December 15, 2037 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BV1 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> BNP Paribas Securities Corp. |
| Co-Managers: | Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

5.500% Notes due 2056

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $3750000000 |
| Coupon: | 5.500% |
| Maturity: | March 15, 2056 |
| Price to Public: | 99.882% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 5.508% |
| Benchmark Treasury: | 4.625% due November 15, 2055 |
| Spread to Benchmark Treasury: | +80 bps |
| Treasury Price and Yield: | 98-21 + / 4.708% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | September 15, 2055 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BW9 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Deutsche Bank Securities Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

FINAL TERM SHEET

5.600% Notes due 2066

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2000000000 |
| Coupon: | 5.600% |
| Maturity: | March 15, 2066 |
| Price to Public: | 99.872% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 5.608% |
| Benchmark Treasury: | 4.625% due November 15, 2055 |
| Spread to Benchmark Treasury: | +90 bps |
| Treasury Price and Yield: | 98-21 + / 4.708% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | September 15, 2065 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |

---

---

| | |
|:---|:---|
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BX7 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**